66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 255 / Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900026883 | 2019-12-01 | 2019-10-25 | A prospective randomized controlled trial of a new method for glucocorticoid intervention in progressive IgA nephropathy | A prospective randomized controlled trial of a new method for glucocorticoid intervention in progressive IgA nephropathy | IgA nephropathy | 1:0.5mg/kg.d prednisolone induced remission;2:0.8mg/kg.d prednisolone induced remission ; | Nephrology Department, Hangzhou Hospital of Traditional Chinese Medicine, Zhejiang Province | NULL | Pending | 18 | 72 | Both | 1:71;2:71; | China | |
| 2 | JPRN-UMIN000032031 | 2018/04/01 | 01/04/2018 | The steroid internal use method for patients with IgA nephropathy | The steroid internal use method for patients with IgA nephropathy - The steroid internal use method for patients with IgA nephropathy | IgA nephropathy | Prednisolone 0.5mg/kg/every other day group Prednisolone 0.25mg/kg/everyday group | Juntendo University | NULL | Recruiting | 20years-old | 100years-old | Male and Female | 100 | Not selected | Japan |
| 3 | NCT02662283 (ClinicalTrials.gov) | May 2016 | 20/1/2016 | Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy | Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy —— A Prospective, Randomized, Controlled, Multi-Center Clinical Trial | IGA Nephropathy | Drug: Prednisolone;Drug: Reh-acteoside | Sun Yat-sen University | NULL | Not yet recruiting | 14 Years | 70 Years | Both | 75 | Phase 2/Phase 3 | China |
| 4 | NCT01451710 (ClinicalTrials.gov) | March 2011 | 7/10/2011 | The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy | The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy | IgA Nephropathy | Drug: Prednisone or Prednisolone | Nanjing University School of Medicine | NULL | Completed | 18 Years | 65 Years | Both | 30 | N/A | China |
| 5 | EUCTR2009-016003-26-GB (EUCTR) | 06/05/2010 | 17/03/2010 | RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : Myfortic | RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : Myfortic | Primary Proteinuric Glomeruolnephritis Focal segmental glomeruloscerosis and IgA nephropathy MedDRA version: 14.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders | Trade Name: Myfortic Product Name: Myfortic 360mg Tablets INN or Proposed INN: mycophenolic acid Other descriptive name: mycophenolate sodium Trade Name: Myfortic Product Name: Myfortic 180mg Tablets INN or Proposed INN: mycophenolic sodium Other descriptive name: mycophenolate sodium Product Name: Prednisolone INN or Proposed INN: prednisolone | UHB NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | United Kingdom | ||
| 6 | EUCTR2007-000443-99-DE (EUCTR) | 09/04/2008 | 13/11/2008 | Comparison of the sequential maintenance therapy with Mycophenolat and Prednisolon to standard therapy after completed induction therapy – a multicenter, randomised, phase III intervention study for progressive IgA-Nephritis | Comparison of the sequential maintenance therapy with Mycophenolat and Prednisolon to standard therapy after completed induction therapy – a multicenter, randomised, phase III intervention study for progressive IgA-Nephritis | progressive IgA-Nephritis MedDRA version: 9.1;Level: LLT;Classification code 10029143;Term: Nephritis-glomerular | Trade Name: Myfortic INN or Proposed INN: Mycophenolat-Natrium Trade Name: Decortin H INN or Proposed INN: Prednisolon | Universitätsklinikum Ulm | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | Germany | |||
| 7 | EUCTR2007-000871-41-DE (EUCTR) | 24/01/2008 | 27/11/2007 | Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP IgAN | Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP IgAN | IgA nephropathy (IgAN) as the most common type of glomerulonephritis. MedDRA version: 16.1;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders | Product Name: Azathioprine INN or Proposed INN: AZATHIOPRINE Product Name: Cyclophosphamid INN or Proposed INN: CYCLOPHOSPHAMIDE Product Name: Prednisolon INN or Proposed INN: PREDNISOLONE Product Name: Methylprednisolon INN or Proposed INN: METHYLPREDNISOLONE Product Name: supportive therapy | RWTH Aachen | NULL | Not Recruiting | Female: yes Male: yes | 148 | Germany | |||
| 8 | JPRN-UMIN000000593 | 2006/11/01 | 05/02/2007 | Randomized controlled trial of mizoribine for progressive IgA nephropathy | IgA nephropathy with moderate to severe histological alterations | Methylprednisolone pulse therapy followed by oral prednisolone administration Methylprednisolone pulse therapy followed by oral prednisolone and mizoribine administration | West Japan Study Group for Therapy of IgA Nephropathy | NULL | Complete: follow-up complete | 15years-old | 60years-old | Male and Female | 120 | Not selected | Japan | |
| 9 | JPRN-C000000341 | 2004/04/01 | 31/03/2006 | Randomised controlled trial of multiple drugs combined therapy for diffuse IgA nephropathy | Refractory IgA nephropathy | Prednisolone and anti-thrombocyte and angiotensin II receptor blocker or angiotensin converting enzyme inhibitor inhibitor mizoribine and Prednisolone and anti thrombocyte and angiotensin II receptor blocker or angiotensin-converting enzyme | Japanese Study Group of Multiple drug therapy for IgAN | NULL | Complete: follow-up complete | 16years-old | 75years-old | Male and Female | 60 | Not selected | Japan | |
| 10 | JPRN-C000000363 | 2001/08/01 | 14/05/2007 | A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial prolideration in children:A randomized controlled trial of efficacy and safety | IgA nephropathy in children | prednisolone+mizoribine for 2 years prednisolone+mizoribine+warfarin+dipyridamole for 2 years | The Japanese Pediatric IgA Nephropathy ofTreatment Study Group | NULL | Complete: follow-up complete | 2years-old | 18years-old | Male and Female | 80 | Not selected | Japan | |
| 11 | JPRN-C000000374 | 1998/08/01 | 01/04/2006 | A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children. | IgA nephropathy in children | prednisolone+warfarin+dipyridamole for 2 years | The Japanese Pediatric IgA Nephropathy ofTreatment Study Group | NULL | Complete: follow-up complete | 2years-old | 18years-old | Male and Female | 20 | Not selected | Japan | |
| 12 | JPRN-C000000375 | 1998/08/01 | 01/04/2006 | A combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with nephrotic syndrome and diffuse mesangial proliferation in children. | IgA nephropathy in children | prednisolone+mizoribine+warfarin+dipyridamole for 2 years | The Japanese Pediatric IgA Nephropathy of Treatment Study Group | NULL | Complete: follow-up complete | 2years-old | 18years-old | Male and Female | 20 | Not selected | Japan |